The ETFO ELHT Benefits Plan announced in May 2022 that plan members or their dependants using Humira, Enbrel, and Lantus would be required to switch to the corresponding biosimilar effective September 1, 2022. A transition period was provided to December 1, 2022. Correspondence via email and Canada Post has been sent regularly since June 2022 to affected plan members. If you still have not made this switch by November 30, 2022, coverage will no longer be available for these three medications effective December 1, 2022.
What you need to do if you have not already made the switch:
If you have any questions about this coverage change under the ETFO ELHT Benefits Plan, please contact OTIP Benefits Services at 1-866-783-6847.
To read the notices emailed to plan members on May 18, 2022, and September 8, 2022, please click on the links below: